AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buurman, E. T.
Right arrow Articles by Schnell, N. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buurman, E. T.
Right arrow Articles by Schnell, N. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2005, p. 2558-2560, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2558-2560.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Utilization of Target-Specific, Hypersensitive Strains of Saccharomyces cerevisiae To Determine the Mode of Action of Antifungal Compounds

Ed T. Buurman,1* Beth Andrews,2 April E. Blodgett,1 Jini S. Chavda,2,{dagger} and Norbert F. Schnell2,{ddagger}

Departments of Microbiology,1 Molecular Sciences, AstraZeneca R&D Boston, Waltham, Massachusetts 024512

Received 14 December 2004/ Returned for modification 18 January 2005/ Accepted 31 January 2005

Target-specific hypersusceptible strains of Saccharomyces cerevisiae were used to screen antifungal compounds. Two novel Erg7p inhibitors were identified, providing proof of principle of the approach taken. However, observed hypersensitivities to antifungals acting via other targets imply that use of this tool to identify the mode of action requires significant deconvolution.

* Corresponding author. Mailing address: AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451. Phone: (781) 839-4592. Fax: (781) 839-4800. E-mail: Ed.Buurman{at}astrazeneca.com.

{dagger} Present address: Cancer Bioscience, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, United Kingdom.

{ddagger} Present address: Fachhochschule Aalen, Beethovenstrasse 1, Aalen 73430, Germany.

Antimicrobial Agents and Chemotherapy, June 2005, p. 2558-2560, Vol. 49, No. 6
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.6.2558-2560.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.